Zhao YR, Hu RH, Wu R, Xu JK. Primary mucosa-associated lymphoid tissue lymphoma in the midbrain: A case report. World J Clin Cases 2021; 9(22): 6566-6574 [PMID: 34435027 DOI: 10.12998/wjcc.v9.i22.6566]
Corresponding Author of This Article
Jian-Kun Xu, MD, PhD, Doctor, Department of Radiation Oncology, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Xicheng District, Beijing 100053, China. xjk_7563@163.com
Research Domain of This Article
Neurosciences
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 6, 2021; 9(22): 6566-6574 Published online Aug 6, 2021. doi: 10.12998/wjcc.v9.i22.6566
Primary mucosa-associated lymphoid tissue lymphoma in the midbrain: A case report
Yong-Rui Zhao, Rong-Hua Hu, Rui Wu, Jian-Kun Xu
Yong-Rui Zhao, Jian-Kun Xu, Department of Radiation Oncology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
Rong-Hua Hu, Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
Rui Wu, Department of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
Author contributions: Zhao YR carried out the literature search and image and data collection, and drafted the manuscript; Hu RH reviewed the literature and drafted the manuscript; Wu R was the pathologist involved in the case, reviewed the literature, and drafted the manuscript; Xu JK made substantial contributions to the manuscript, including revising it critically for intellectual content; all authors read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to report.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian-Kun Xu, MD, PhD, Doctor, Department of Radiation Oncology, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Xicheng District, Beijing 100053, China. xjk_7563@163.com
Received: April 12, 2021 Peer-review started: April 12, 2021 First decision: April 23, 2021 Revised: May 1, 2021 Accepted: May 15, 2021 Article in press: May 15, 2021 Published online: August 6, 2021
Abstract
BACKGROUND
Primary non-dural central nervous system mucosa-associated lymphoid tissue (MALT) lymphoma is a rare indolent B-cell lymphoma, with only a few reported cases worldwide.
CASE SUMMARY
A 33-year-old man presented with a 5-mo history of left blepharoptosis and a 4-mo history of right limb numbness and weakness. Magnetic resonance imaging showed a significantly enhanced mass in the left midbrain. Subsequent positron emission tomography revealed that the lesion had increased glucose uptake. A stereotactic robotic biopsy supported a diagnosis of MALT lymphoma. Then he was treated with radiation therapy (30Gy/15F), which resulted in complete remission. We also review the literature on brain parenchymal-based MALT lymphoma, including the clinical presentation, treatment options, and outcomes.
CONCLUSION
Although there is no consensus on the optimal treatment for this rare disease, patients can respond well when treated with radiotherapy alone.
Core Tip: Primary central nervous system mucosa-associated lymphoid tissue (MALT) lymphoma is a rare disease, especially in the brain parenchyma. A clear diagnosis is important because it can be cured. This report presents the treatment of MALT lymphoma developing in the midbrain. The patient received local radiotherapy and was in complete remission without apparent adverse effects.
